Phenylquinoline PPARα Agonists for Retinal Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal inflammation and neovascularization in ocular disorders like diabetic retinopathy and age-related macular degeneration, such as fenofibrate, have limitations including low binding affinity for PPARα and off-target side effects, necessitating the development of higher affinity agonists to improve therapeutic outcomes.
Innovation Solution
Development of a new class of phenylquinolone derivatives with distinct structures that act as PPARα agonists, enhancing transcriptional activity and exhibiting anti-inflammatory and anti-angiogenic effects, thereby providing therapeutic benefits for retinal disorders without the limitations of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fenofibrate is used to treat diabetic retinopathy, then therapeutic effects are achieved, but binding affinity for PPARα is low and off-target side effects occur
Solution Approach 1:
The patent modifies the chemical structure of fenofibrate by replacing the phenyl group with a phenylquinoline moiety and adjusting substituent patterns. This structural parameter change increases binding affinity for PPARα while maintaining therapeutic effects, thereby reducing the dose required and minimizing off-target side effects.
Solution Approach 2:
The invention creates composite molecular structures by combining phenyl and quinoline rings with specific substituent groups (halogens, alkoxy, carboxylic acid). This composite structure optimizes the balance between PPARα binding affinity and selective agonist activity, improving therapeutic index.
2Reliability
If fenofibrate is used to treat diabetic retinopathy, then therapeutic effects are achieved, but binding affinity for PPARα is low
Solution Approach 1:
The patent systematically varies structural parameters including the introduction of electron-withdrawing halogen substituents (fluorine, chlorine, bromine) at specific positions on the phenylquinoline ring, adjustment of alkoxy group positions, and optimization of carboxylic acid placement. These parameter changes enhance electrostatic interactions and hydrogen bonding with PPARα, increasing binding affinity by several-fold compared to fenofibrate.
Solution Approach 2:
The invention introduces specific local structural features such as chlorine substitution at the 7-position and methoxy groups at 8,9-positions of the phenylquinoline ring. These localized modifications create optimal interaction zones with PPARα binding pocket, enhancing binding affinity without compromising overall molecular stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The phenylquinolone derivatives demonstrate potent PPARα agonistic activity, effectively reducing retinal inflammation and neovascularization, offering improved therapeutic effects compared to existing agents with enhanced safety profiles.
Implementation Method 1
PPARα forms a heterodimer with retinoid x receptor (RXR) and binds to the PPAR responsive element (PPRE) in the promoter of its target genes and, activating target gene transcription
Data Source
AI summary
Compositions containing a phenylquinoline derivative compound having peroxisome proliferator-activated receptor a (PPARα) agonistic activity, and methods of their use in enhancing PPARα activity in retinal cells, and in treating ocular disorders or conditions, such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.